acute myeloid leukemia

[Leukemia] Recurrent mutations in IDH1 or IDH2 in acute myeloid leukemia (AML) are associated with increased DNA methylation. Scientists analyzed whole-genome bisulfite sequencing data from 15 primary AML samples with IDH1 or IDH2 mutations,

[Proceedings of the National Academy of Sciences of the United States of America] Using exome sequencing, RNA-sequencing, and functional immunologic studies, scientists characterized 28 normal karyotype (NK)-AML patients with over 5 year first remissions after chemotherapy and compared them to a well-matched group of 31 NK-AML patients who relapsed within two years.

[Haematologica] PVRIG blockade significantly enhanced NK-cell killing of poliovirus receptor-related 2 (PVRL2)+, poliovirus receptorlo AML cell lines, and significantly increased NK-cell activation and degranulation in the context of patient primary AML blasts.

[Kura Oncology, Inc.] Kura Oncology, Inc. announced that the US FDA has placed the KOMET-001 Phase Ib study of KO-539 in patients with relapsed or refractory acute myeloid leukemia on a partial clinical hold following the company’s recent report of a Grade 5 serious adverse event (patient death) potentially associated with differentiation syndrome.

[Leukemia] Researchers reported the development of an acute myeloid leukemia cell membrane-coated nanoparticle vaccine platform, in which immune-stimulatory adjuvant-loaded nanoparticles were coated with leukemic cell membrane material.

[Leukemia Research] Scientists discuss in detail the mechanisms involved in accumulation of cadmium in particular cell lines of the bone marrow and the consequent occurrence of acute myeloid leukemia.